Background: Opioid analgesic use and associated adverse events have increased over the
However, other studies have found no significant differences in the prevalence of chronic pain between males and females. 15, 16 In Australia and elsewhere, opioid analgesia is generally indicated for pain that is considered moderate to severe. [17] [18] [19] Thus, in addition to pain of extended duration as reflected by chronic pain status, information on pain severity should also be assessed to ensure use is consistent with prescribing recommendations. As a counterpoint, equivalent data on non-opioid analgesia can provide further insight into the use of opioid analgesics in recent pain, by severity and in those with chronic pain. Whether the increased use of opioid analgesia in the Australian population is associated with a change in chronic pain prevalence over time, or is solely associated with other factors is currently unknown. Furthermore, an assessment of the appropriateness of opioid analgesia use in association with pain severity, given current prescribing recommendations, is also needed. Therefore, using the Australian National Health Survey (NHS), this study will (1) estimate current prevalence of chronic pain and analgesia use in the Australian population by and age and sex; (2) determine severity of pain in the population with chronic pain by sex; and (3) assess the distribution of recent pain severity in those using analgesia, by age and sex.
2 | METHODS
| Participants
This study used cross-sectional, nationally representative data col- ing national benchmarks on many health-related issues and health trends over time. 20 The sample consisted of persons of all ages living in private Australian residences, collected via stratified multistage sampling. 20 The sample design ensured that within each state of Australia, each person had an equal chance of selection. Survey information was obtained for 1 adult and 1 child aged 0 to 17 years (if applicable) in each participating household. 20 Face-to-face interviews were conducted by trained ABS interviewers in participants' homes between the periods of March 2011 to March 2012. 20 The overall response rate was 84.8%, with a total of n = 20 426 participants from 15 565 private residences. 21 Data are made available by the ABS in the form of a Confidentialised Unit Record File (CURF). The CURF contains detailed, individual participant data which have been collected by the ABS for the purposes of census and population surveys. 22 These data are made available at the discretion of the ABS on the condition that participant identity is not available to users of the CURF and participant confidentiality is always retained. 22 For this reason, not all data collected within a survey may be included in the CURF, and there are restrictions on allowable analyses.
| Data and analysis
Chronic pain was defined as self-reported pain which persisted or reoccurred over a 6-month period. "bodily pain" was defined as pain experienced within the previous 4 weeks and measured by severity of pain experienced on a scale from "no pain" to "very severe" pain.
To reflect prescribing recommendations for opioid analgesic medications (treatment of moderate to very severe pain), pain severity was classified into 4 groups: no pain, very mild to mild pain, moderate to very severe pain, and not applicable or unknown. As chronic pain
gives an indication of pain duration and bodily pain provides information on recent pain severity, use of both variables allowed investigation of the severity of chronic pain and whether opioid analgesia use was appropriately associated with pain severity given prescribing recommendations.
Participants were asked for the name or brand of all medication they had taken in the last 2 weeks and were requested to provide the packages of all recently used medications to the interviewer to assist in the recording process. Medications were classified using Of males who were ≥15 years of age, 14.6% were living with chronic or reoccurring pain, and likewise for 16.1% of females.
The distribution of the Australian population aged ≥15 years living with chronic or reoccurring pain and the percentages using opioid analgesia by 10-year age groups by sex is illustrated in Figure 1 . The prevalence of chronic or reoccurring pain generally increased with age for both males and females. Over 12% of females ≥85 years reported any opioid analgesia use in the 2 weeks prior to the survey.
There was a trend towards higher opioid use in females than males in every age group.
The percentage of those reporting chronic or reoccurring pain and taking opioid analgesia are represented in Figure 2A . An estimated 12.0% of males and 13.4% of females with chronic or reoccurring pain aged ≥15 years had taken opioid analgesic medications in the previous 2 weeks, with the highest percentages of use seen in the youngest (17.0%) and oldest (29.0%) female age groups.
The percentages of those reporting chronic or reoccurring pain and taking non-opioid analgesia are represented in Figure 2B . In those aged ≥15 years, almost a quarter (23.1%) of males and over a quarter (29.2%) of females with chronic or reoccurring pain had taken nonopioid analgesic medications in the previous 2 weeks, with both males (57.6%) and females (63.9%) aged ≥85 years reporting the highest percentages of use.
| Pain severity in persons with chronic pain
The distribution of reported pain severity over the last 4 weeks in persons aged ≥18 years with chronic or reoccurring pain is shown in Table 1 . Most males (63.8%) and females (72.2%) with chronic or recurring pain stated their pain was moderate to very severe over the 4 weeks prior to the survey. Relative standard error between 25% and 50%.
c Totals do not equal 100%, data for persons who responded "not applicable" or were unknown were not provided. When broken down by sex, males were significantly more likely overall to report no pain (P < 0.001) or be in the not applicable/ unknown category (P < 0.001), and females were significantly more likely to report moderate to very severe pain (P = 0.001). A detailed breakdown of pain severity by age group for both males and females is provided in Table 2 .
Statistically significant differences were also noted in pain severity experienced by males and females within most age ranges across 3.4 | Distribution of pain severity in persons using analgesia Figure 3A ,B illustrates the distribution of pain severity in males and females aged ≥15 years using opioid analgesia in the previous 2 weeks. In each age group, except males aged 15 to 24 years, most individuals using opioid analgesia reported moderate to very severe pain, followed by very mild to mild pain. However, in males aged 15 to 24 years, the percentage reporting no pain and having used opioid analgesia in the previous 2 weeks (32.7%) was higher than those reporting very mild to mild pain (13.2%). In no other age range did males (or females) report "no pain" while also reporting recent opioid use to the extent seen in the youngest male group. There was not enough evidence to reject the null hypothesis of no difference between males and females of each age group using opioid analgesia for any level of pain severity. 14 Similar estimates of chronic pain prevalence, 20% of females and 18% of males, were reported in a recent national study on patients, including children, seeking medical treatment from a General Practitioner. 16 However, differences in inclusion criteria in the study of general practice patients require these results to be considered stand-alone.
In interpreting the results of the current study, it is also important to consider variations in definitions of chronic pain. The ABS defined chronic pain as self-reported pain which persisted or reoccurred over a 6-month period, similar to the definition used in a recent Danish study of population survey data. 24 By contrast, Blyth et al (2001) and most other published Australian studies define chronic pain as pain occurring every day, over a 3-month period within the most recent 6 months. [14] [15] [16] 25 The ABS definition used for the current study is thus arguably less stringent, which would be expected to lead to higher estimates of prevalence, rather than the lower estimates observed. Thus, it is apparent that the prevalence of chronic pain in the current study is no greater than these earlier estimates. In turn, there is no evidence to support an increase in chronic pain prevalence since the Blyth et al (2001) study, and certainly not to the extent of the 15-fold increase in opioid analgesia dispensing episodes within the Australian population between 1992 and 2012. 4 Further, the increase in opioid use reported in the literature cannot be ascribed to an increase in the overall proportion experiencing any bodily pain as the percentage of the population aged 18 years and above experiencing any bodily pain has remained constant at 68% from the 2007 to 2008 NHS, 26 to the current study. However, it is possible that an increase in pain severity in those with chronic pain over time could account for some of the increase in opioid use.
Many of the other findings noted earlier also show similarities to those found in the published literature. First, the estimate of opioid use in the Australian population with chronic pain, at 12% for males and just over 13% for females, and the 12% reported for Denmark. 27 Second, the estimate that just over two thirds of all Australians aged ≥18 years had experienced some pain during the last 4 weeks shows some comparability to the 55.7% reported for the US population in 2012. 13 Third, the finding that moderate to very severe pain was more prevalent in females across most age groups is consistent with previous findings of epidemiological and experimental research. 28 Nahin (2015) also found that females in the US population had a higher prevalence of more severe pain, but only in specific language and cultural groups 13 Fourth, the majority of those using opioid analgesia also reported recent moderate to very severe pain, similar to a large, cross-sectional study of n = 10 066 participants in Denmark. 29 This is also consistent with current prescribing recommendations in Australia 17 and by the World Health Organisation. 18 Also consistent with previous research is the relatively high use of opioid medications in the elderly seen in this study. Pain severity in Australians aged ≥15 years using non-opioid analgesic medications, by 10-year age group and sex, A, females B, males. Error bars represent 95% confidence intervals care excluded. 31 Likewise, opioid prescriptions for both morphine and oxycodone have been reported as most common among elderly Australians aged ≥80 years. 3 Given that opioid use in older people has been associated with an increased risk of medicationrelated hospitalisations and numerous adverse events including falls causing injury, fracture, dizziness, and delirium, 4,32,33 our findings re-emphasise the concerns raised in these previous studies.
As differences between male and female use of opioid analgesia in those with chronic pain were very apparent in the current study, we reiterate the call from Darnall, Stacey and Chou (2012) for future research to explore sex differences in more depth and to provide more detailed analysis on these themes. 9 The importance of sex differences is reflected in previous Australian research which demonstrated that females are more likely than males to intentionally overdose on opioid analgesia, specifically codeine. 34 Further, special consideration should be given to women of reproductive age. While it is imperative that females of reproductive age receive analgesic medication as medically indicated, it also is vital to allow them to make an informed decision on the risks and benefits of ongoing use of analgesic medication should pregnancy occur. 35 Additional epidemiological research is also needed to understand treatment option availability and utilisation, including the impact of treatment availability on daily functioning and quality of life of people living with pain conditions in Australia.
The strengths of this study include the use of data collected as part of the 2011 to 2012 Australian NHS in a robust and rigorous manner by trained staff of the ABS, with a response rate of over 80%. We are limited, however, by the fact that this survey relies mainly upon self-reported data. While this may be less of an issue for subjective, pain-related variables where self-report is considered the gold standard, 36 self-report of medication use may not be as robust as medical record audit or linkage of prescription data. 13 If so, our results will likely underestimate the proportion of the Australian population taking opioid and non-opioid analgesia. However, as participants were asked to physically provide the interviewer with all medications taken over the previous 2 weeks, this study's findings are strengthened compared with self-reported medication use alone.
Persons in hospital and other care facilities were not sampled, and the wide confidence intervals for some data are likely reflective of smaller sample sizes in the youngest and oldest age groups. Further analysis of chronic pain data was not possible due to data access restrictions. We were also limited by the specific questions asked within the survey. While chronic pain and medication use was asked of participants of all ages, questions about pain severity were only asked to participants aged ≥18 years. We were not able to distinguish whether the reported severity of bodily pain changed due to analgesia use. We were also not able to distinguish whether analgesia taken was prescribed or purchased "over the counter". This survey is also unlikely to accurately capture non-adherent or illicit use of analgesic medications. We reiterate calls for future research to explore sex differences in the utilisation of analgesia in more depth. We also call for more detailed analysis relating to the use of opioid analgesia in those with chronic pain, including assessment of daily functioning, patient satisfaction, and quality of life.
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